Sunovion Pharms Inc patent expiration

1. Latuda patent expiration

LATUDA IPR and PTAB Proceedings
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US5532372 SUNOVION PHARMS INC Imide derivatives, and their production and use
Jul, 2018

(6 years ago)

USRE45573 SUNOVION PHARMS INC Process for producing imide compound
Jun, 2025

(11 months from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US5532372 SUNOVION PHARMS INC Imide derivatives, and their production and use
Jul, 2018

(6 years ago)

US5532372

(Pediatric)

SUNOVION PHARMS INC Imide derivatives, and their production and use
Jan, 2019

(5 years ago)

US9815827 SUNOVION PHARMS INC Agent for treatment of schizophrenia
Feb, 2024

(4 months ago)

US9174975 SUNOVION PHARMS INC Remedy for integration dysfunction syndrome
Feb, 2024

(4 months ago)

US9174975

(Pediatric)

SUNOVION PHARMS INC Remedy for integration dysfunction syndrome
Aug, 2024

(a month from now)

USRE45573

(Pediatric)

SUNOVION PHARMS INC Process for producing imide compound
Dec, 2025

(1 year, 5 months from now)

US8883794 SUNOVION PHARMS INC Pharmaceutical composition
May, 2026

(1 year, 10 months from now)

US9555027 SUNOVION PHARMS INC Pharmaceutical composition
May, 2026

(1 year, 10 months from now)

US8729085 SUNOVION PHARMS INC Pharmaceutical composition
May, 2026

(1 year, 10 months from now)

US9907794 SUNOVION PHARMS INC Pharmaceutical composition
May, 2026

(1 year, 10 months from now)

US8883794

(Pediatric)

SUNOVION PHARMS INC Pharmaceutical composition
Nov, 2026

(2 years from now)

US8729085

(Pediatric)

SUNOVION PHARMS INC Pharmaceutical composition
Nov, 2026

(2 years from now)

US9907794

(Pediatric)

SUNOVION PHARMS INC Pharmaceutical composition
Nov, 2026

(2 years from now)

US9827242 SUNOVION PHARMS INC Method of treatment for mental disorders
May, 2031

(6 years from now)

US9259423 SUNOVION PHARMS INC Method of treatment for mental disorders
May, 2031

(6 years from now)

US9259423

(Pediatric)

SUNOVION PHARMS INC Method of treatment for mental disorders
Nov, 2031

(7 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Dosing Schedule(D-134) Apr 26, 2015
New Chemical Entity Exclusivity(NCE) Oct 28, 2015
New Indication(I-674) Jun 28, 2016
M(M-195) Jan 27, 2020
Pediatric Exclusivity(PED) Jul 27, 2020
New Patient Population(NPP) Mar 05, 2021

Drugs and Companies using LURASIDONE HYDROCHLORIDE ingredient

NCE-1 date: 28 July, 2019

Market Authorisation Date: 07 December, 2011

Treatment: Treatment of schizophrenia; Treatment of schizophrenia with improvement in negative symptoms and/or cognitive dysfunction of schizophrenia; Treatment of schizophrenia with improvement in attention fun...

Dosage: TABLET

How can I launch a generic of LATUDA before it's drug patent expiration?
More Information on Dosage

LATUDA family patents

Family Patents